Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

BackgroundThe trastuzumab biosimilar CT-P6 has demonstrated equivalent efficacy and comparable safety to reference trastuzumab (RTZ) in clinical trials of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC). Here, we present the first real-world comparison of CT-P6 ver...

Full description

Bibliographic Details
Main Authors: Soong June Bae, Jee Hung Kim, Sung Gwe Ahn, Hei-Cheul Jeung, Joohyuk Sohn, Gun Min Kim, Min Hwan Kim, Seung Il Kim, Seho Park, Hyung Seok Park, Ji Ye Kim, Joon Jeong
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
biosimilar
HER2-positive breast cancer
trastuzumab
CT-P6
early breast cancer (EBC)
metastatic breast cancer (mbc)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.689587/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.689587/full

Similar Items